Pertussis toxin (PT) protein, which is the most important protective antigen of Bordetella pertussis, has a hexameric structure composed of five subunits, designated Si through S5. Immunoprotective activity of 20 different mouse monoclonal antibodies (MAbs) against pertussis toxin, 10 anti-Si, 1 anti-S2, 2 anti-S3, 4 anti-S23, and 3 anti-S4 antibodies, were investigated by aerosol and intracerebral challenges with virulent B. pertussis organisms in mice. Four anti-Si, named 1B7, 1D7, 3F11, and 1OD6, and three anti-S23 antibodies, named 11E6, 1OB5, and 1OC9, showed the highest, and almost complete, protectivity against the aerosol challenge. Mouse protectivity against the intracerebral challenge was significant for these four anti-Si MAbs but not for any of the three anti-S23 MAbs. Four anti-Si and two anti-S4 MAbs did not protect the mice against either challenge. The other seven MAbs also showed dose-dependent moderate but signfficant protection against the aerosol challenge. In the aerosol challenge system, bacterial numbers and amounts of PT detected in the lung and the number of peripheral leukocytes were lower in the mice given the protective MAbs. All mice surviving 5 weeks after the infection produced high titers of antibodies against PT, ifiamentous hemagglutinin (FHA), and agglutinogens from the challenge organisms. A combination of the protective MAbs 1B7 and 11E6 strongly suppressed the disease and mortality of the mice at smaller amounts than with the anti-PT polyclonal antibody. Although combinations of one of the protective MAb and anti-FHA or anti-agglutinogen 2 also showed extremely high mouse protection without development of symptoms of the disease, antibody titers of the survivors against PT, FHA, and agglutinogens were significantly low. The foregoing results suggest that some important protective epitopes should be in Si and S2 and/or S3, although there are both differences and similarities in the protective roles between anti-Si and anti-S23 antibodies and also in the pathogenic mechanisms between aerosol and intracerebral infections. Furthermore, it was suggested that although not only FHA and agglutinogen 2 but also PT have roles as attachment factors, the processes of infection and protection are different between mice immunized with antibody against FHA or agglutinogen 2 and that against PT because the latter mice are also able to neutralize toxicity of PT diffused into the mice.
The importance of pertussis toxin (PT) as a protective antigen of pertussis vaccine has been demonstrated by the results of a field trial with pure pertussis toxoid in Sweden (21) as well as the results of mouse protection experiments in the laboratory (8, 9, 11, 13, 17) . PT has many different biological and toxic activities caused by its complicated hexameric structure consisting of five different subunits, designated Si through S5. The toxicity of PT is considered to be generated by the A (active) protomer, Si, with ADPribosyltransferase activity in cooperation with the B (binding) oligomer composed of two dimers, S24 and S34, and one S5 and to be related to some of the undesirable side effects. Which antibodies against which subunits or epitopes are important in the prevention of pertussis disease? Which antibodies should be produced by the vaccination? To improve the PI antigen in the vaccine for a safer and more potent antigen, the protective epitopes on PT should be dissected and these questions should be answered.
We have been studying immunoprotective and antitoxic properties of five monoclonal antibodies (MAbs) against PT, two anti-Si and one anti-S2, S23, and S4 antibody each (12, 14, 15) . One of the anti-Si MAbs, 1B7, showed highly potent mouse protectivity against either aerosol or intracerebral (i.c.) challenge with Bordetella pertussis as well as therapeu-* Corresponding author. tic activity for the disease (12, 14) . The anti-S23 MAb, 11E6, also protected mice against the aerosol challenge but not against the i.c. challenge (14) . Although several other laboratories have published papers on MAbs against PT (1, 2, 5, 7, 20) , there has been no report focusing on the immunoprotectivity of MAbs against different subunits. No other group has reported on the protectivity of anti-B oligomer antibody against challenge with virulent B. pertussis organisms.
In this study, we investigated the mouse protectivity of 20 different anti-PT MAbs, 10 anti-Si, 1 anti-S2, 2 anti-S3, 4 anti-S23, and 3 anti-S4 antibodies, in aerosol challenge and i.c. challenge systems with B. pertussis to expand and confirm previous results and to determine the location of the most important epitopes for immunoprotectivity. The role of specific antibodies against different protective epitopes in immunity of mice to pertussis infection and disease was investigated by a combination of antibodies not only against PT but also against filamentous hemagglutinin (FHA) and agglutinogen 2 (Agg 2), which were also considered to be effective protective antigens.
The other purpose of this study was to provide reference antibody preparations by the mixing of several MAbs suitable for assay of PT and of anti-PT antibody and for quality control or evaluation of the vaccine. To determine a reasonable composition and the constant proportions of the antibodies as a reference, it is essential to know the protective properties and activity of each MAb.
MATERIALS AND METHODS
Preparation of MAbs. A hybridoma of spleen cells of a BALB/c mouse and myeloma SP2/0 was generated twice previously (12, 15) and kept in liquid nitrogen after screening for antibody production but without cloning. The frozen hybridoma was taken out of the nitrogen to select the hybridoma cells which produce different MAbs from those already characterized (12, 15 25 and 9 ELISA U/ml, respectively, the effect of these antibodies on the protection experiments was considered negligible.
Assay of antibody titer. Antibodies against PT or FHA were measured by the ELISA system, and ELISA units per milliliter were estimated from the dose-response curves by the reference line assay method with anti-PT, M6, or anti-FHA mouse PAbs, respectively, as reference, as reported previously (13) . The agglutinin titer was estimated by agglutination with B. pertussis, strain 18323, in a microplate (13) .
Mouse protection test against aerosol challenge. Mouse protection tests were carried out as described previously (16, 18) . Suckling mice (6 days old) were immunized passively with 0.2 ml of the antibody by intraperitoneal injection 2 h before aerosol challenge with B. pertussis strain 18323.
Aerosol challenge was performed by using improved aerosol inhalation equipment to permit the reproducible and uniform infection of 500 mice simultaneously in a relatively short time. Two hundred and fifty suckling mice (removed temporarily from their mothers for the exposure) were placed in a transparent aerosol chamber (120 x 120 x 40 cm) with 50 compartments. The suckling mice were exposed for 30 min to an aerosol generated from the bacterial suspension (109/ ml) at a nebulizer pressure of 1.5 7E10 and 7G11; anti-S23, G9A; and anti-S4, 6G8, showed moderate protection, although the protective activity of each MAb depended on the dose of IgG administered. The lower the leukocyte count and the greater the body weight, the higher the survival rate. Almost all MAbs showing significant mouse protection provided the mice with significant antibody production against three antigens, PT, FHA, and agglutinogens from the challenge strain. Mouse-protecting activity of the MAbs was also investigated by using the i.c. challenge system. Six-week-old female SPF ddY mice were immunized intraperitoneally with 40 ,ug of the purified MAb IgG preparations, challenged i.c. with B. pertussis strain 18323 (50,000 cells per mouse per 25 RIl) 3 h after the immunization and then observed for 2 weeks. The survival rate of the mice 2 weeks after the challenge is shown in Experiment B in Table 1 . Anti-Si MAbs, which showed high protectivity in the aerosol system, also protected mice significantly against the i.c. challenge. Antibodies against other subunits (B oligomer) showed little or no protection in the i.c. challenge system, even though they showed high protectivity against the aerosol challenge.
The effect of MAbs on bacterial growth in the lung. The effect of MAbs on bacterial growth and PT production in the respiratory tract of mice challenged with B. pertussis was examined. The CFU, amount of PT in the lungs, and leukocyte counts in peripheral blood in the second week are shown in Table 2 . These protective MAbs, regardless of their binding subunit(s), suppressed not only PT activity but also bacterial growth in the lungs. In the i.c. challenge system, 1B7 given by intraperitoneal injection also suppressed bacterial growth in the brain and saved the mouse from death (data not shown).
Effect of combinations of anti-PT MAbs and PAbs against FHA and Agg 2. The effect of a mixture of two MAbs on their mouse-protective activities in the aerosol challenge system was examined by using various combinations of MAb. The combination of anti-Si and anti-B oligomer MAbs tended to elicit higher protectivity than the combination of intrasubunit or inter-B oligomer antibodies. The combination of 1B7 (anti-Si) and 11E6 (anti-S23) was one of the most effective. As shown in Table 3 , the mixture of 2.5 ,ug of 1B7 and 7.5 ,ug of 11E6 showed higher protective potency than 30 ,ug of anti-PT PAb, M5. Effects of combinations of anti-FHA or anti-Agg 2 and 1B7, 11E6, or M5 on mouse protectivity were also examined. Any combination of one of the former and the latter antibodies showed strong protection, but the antibody titers of survivors after 5 weeks were lower than those of survivors immunized with anti-PT antibodies alone. These cooperative effects of the different antibodies on mouse protection were confirmed not only by the lower bacterial number and reduced production of PT in the lungs but also by fewer histopathological changes in the lungs. The therapeutic activities of antibodies. The therapeutic activities of these antibodies were examined. The antibody was given by intraperitoneal injection 2 h before (day 0), at three days (day 3), or at seven days (day 7) after the aerosol challenge. Leukocytes and insulin in the peripheral blood were measured 3, 7, 14, 21 , and 35 days after the challenge. In Table 4 , leukocyte counts and insulin units after 2 weeks and the survival rate after 3 weeks are shown. All three anti-PT antibodies showed full protection when the antibody was administered by 3 days after the challenge. Even after 7 days, some therapeutic effect was shown. Earlier administration gave better protection. On the other hand, neither anti-FHA nor anti-Agg 2 showed significant therapeutic effects.
Histopathological observation of the lungs. In the lungs of mice challenged with the organisms, alveolitis in the acute stage proceeded to septal pneumonitis and hyperplasia of the bronchial and perivascular lymphoid tissue was observed for long periods with administration of anti-PT antibody. If the mice were not given any antibody, most of them died during the acute stage of alveolitis. In mice immunized with anti-FHA or anti-Agg 2, hyperplasia of the lymphoid tissue was not so severe. With the combination of anti-PT and anti-FHA or anti-Agg 2, both alveolitis and septal pneumonitis were clearly suppressed. We have reported that a combination of two MAbs, especially anti-Si and anti-B oligomer, showed higher specific activity in in vitro and in vivo PT neutralization assays than anti-PT PAb (15) . In the aerosol challenge experiments, a combination of anti-Si, such as 1B7, and anti-S23, such as 11E6, showed almost complete protection of mice with 10 ,ug of IgG of the mixed antibody. This amount was significantly less than that of anti-PT PAb, which showed the same protectivity.
We checked the effects of nine protective MAbs, six anti-Si and three anti-S2 and/or S3 MAbs, on bacterial growth and PT production in the lungs. These protective MAbs decreased the number of bacteria and amount of PT detected in the lungs. This result suggested that the role of the anti-PT antibody in mouse protection is not only neutralization of PT penetrating the mouse but also prevention of bacterial growth in the respiratory tract. This result also supported the finding that PT has a role as an attachment factor (22) . In the aerosol challenge experiments, both anti-Si and anti-S2 and/or S3 showed similar protective properties, although anti-Si antibody seemed to be more potent than anti-S23 antibody in the i.c. challenge system. Bacterial growth in the brain of the mice was also suppressed with anti-Si, 1B7. These results suggested that there are both differences and similarities in the protective roles between anti-Si and anti-S23 and also in the pathogenic mechanisms between aerosol and i.c. infections.
FHA and Agg 2 are considered to be attachment factors and protective antigens (6, 10) , but the mode of action of these two antigens must be different from that of PT. Anti-PT antibody showed therapeutic effects on the infected mice, but anti-FHA and anti-Agg 2 did not (Table 4) . Furthermore, antibody production of the survivors and pathological observations of the lungs also suggested that the processes of infection and protection are different between mice immunized with antibody against FHA or Agg 2 and that against PT, whereas they might be similar or the same in mice immunized with anti-FHA and anti-Agg 2 antibodies. In aerosol challenge experiments, mice surviving due to administration of a potent protective anti-PT MAb produced significant titers of antibodies against PT, FHA, and agglutinogens (Tables 1 and 3 ). However, the mice which survived due to immunization with anti-FHA or anti-Agg 2 together, with or without protective anti-PT MAb, produced few antibodies (Table 3) . Bacterial 58, 1990 on December 21, 2017 by guest http://iai.asm.org/ Downloaded from the mice must be too small to act as effective immunogens. However, PT could have caused specific toxic action such as leukocytosis in the mice if anti-PT antibody had not been administered and made them ill, even though they did not die. On the other hand, since anti-PT antibody has two roles, prevention of bacterial adherence and neutralization of toxicity, bacterial growth in the lungs is suppressed, pertussis symptoms caused by the limited amount of PT produced and diffused in the mice are controlled and the mice acquire immunity against pertussis infection.
We have not found a significant role in mouse protection from among three anti-S4 MAbs, 1H2, 6G8, and 9F3. Addition of anti-S4, 1H2, to 1B7 and/or 3F10 did not show any effect (12) . It is not known if an anti-S4 antibody can bind to PT together with protective antibodies against Si, S2, and S3 without disturbing their protectivity by steric hindrance or conformational changes. Recently, we have generated anti-S5 as well as anti-S4 MAbs in order to find a role of these antibodies in PT neutralization and mouse protection and in the biological activities of PT.
Naturally, the slope of the dose-response curves in PT neutralization with a single MAb was not as steep as that for PAb, but a combination of multiple MAbs made it steeper. With the combination of 1B7 and 11E6, the slope was the same as that for PAb (15) . This property is important for generation of the reference antibody. The effect of combinations of MAbs on the activities of the mixture must be investigated further to decide a reasonable composition and the proportions of MAbs in the reference antibody.
